肿瘤细胞治疗研究
英文原题：Molecular mechanisms of Epstein-Barr Virus in the pathogenesis of lymphomas and new opportunities for precision medicine.
Molecular mechanisms of Epstein-Barr Virus in the pathogenesis of lymphomas and new opportunities for precision medicine.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
爱泼斯坦—巴尔病毒（EBV）是一种与多种淋巴瘤密切相关的疱疹病毒，可通过诱导基因组不稳定、重塑关键信号通路及逃避免疫监视等多种机制促进肿瘤发生。在伯基特淋巴瘤（BL）中，MYC基因异常激活被认为是关键驱动事件；近期研究指出，EBV核抗原1（EBNA1）和潜伏膜蛋白1（LMP1）可通过调控宿主染色质结构及抗原呈递过程，显著增强肿瘤细胞增殖和免疫逃逸。在弥漫性大B细胞淋巴瘤（DLBCL）和霍奇金淋巴瘤（HL）中，LMP1和潜伏膜蛋白2A（LMP2A）等EBV潜伏蛋白可激活NF-κB和JAK/STAT信号通路，重塑肿瘤微环境、增强抗凋亡生存信号并促进免疫抑制。
此外，EBV编码的微小RNA和长链非编码RNA（lncRNA）进一步调节宿主基因表达及代谢通路，增加肿瘤异质性和治疗耐药。尽管靶向MYC、PI3K/AKT通路和免疫检查点已有进展，但耐药、高毒性和肿瘤微环境复杂性仍限制其临床应用。CAR-T 细胞疗法、EBV特异性T细胞疗法和表观遗传靶向等新兴免疫疗法，有望优化免疫微环境并克服治疗耐药。
然而，EBV相关淋巴瘤的分子异质性给精准医疗带来更大挑战。未来研究需整合多组学数据，阐明EBV与宿主之间复杂的分子相互作用，为开发多靶点联合疗法及创新诊疗方法奠定基础。本综述系统总结EBV促进淋巴瘤发生的核心机制，并评估当前治疗策略的突破与挑战，同时概述基于多学科整合的精准医疗未来方向，以深化对EBV相关淋巴瘤分子病理的认识并优化个体化治疗。
Epstein-Barr Virus (EBV), a herpesvirus closely linked to multiple types of lymphoma, promotes tumorigenesis through various mechanisms, including inducing genomic instability, reprogramming key signaling pathways, and evading host immune surveillance. In Burkitt Lymphoma (BL), aberrant activation of the MYC gene is recognized as a pivotal driver event, while recent reports indicate that EBV nuclear antigen 1 (EBNA1) and latent membrane protein 1 (LMP1) significantly enhance tumor cell proliferation and immune evasion by regulating host chromatin structure and antigen presentation processes.
In Diffuse Large B cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL), EBV latent proteins such as LMP1 and latent membrane protein 2A (LMP2A) activate the NF- B and JAK/STAT signaling pathways, reshaping the tumor microenvironment, enhancing anti-apoptotic survival signals, and promoting immune suppression.
Furthermore, EBV-encoded microRNAs and long non-coding RNAs (lncRNAs) further modulate host gene expression and metabolic pathways, increasing tumor heterogeneity and therapeutic resistance. Despite advances in targeting MYC, the PI3K/AKT pathway, and immune checkpoints, issues such as resistance, high toxicity, and the complexity of the tumor microenvironment limit their clinical applicability.
Emerging immunotherapies, including CAR-T cell therapy, EBV-specific T-cell therapy, and epigenetic targeting, show significant potential in optimizing the immune microenvironment and overcoming therapeutic resistance.
However, the molecular heterogeneity of EBV-associated lymphomas poses greater challenges for precision medicine strategies. Future research needs to integrate multi-omics data to elucidate the complex molecular interactions between EBV and its host, laying the groundwork for the development of multi-targeted combinatorial therapies and innovative diagnostic and therapeutic approaches.
This review systematically summarizes the core mechanisms by which EBV contributes to lymphoma pathogenesis and evaluates the breakthroughs and challenges of current therapeutic strategies. It also outlines the future directions of precision medicine, based on multi-disciplinary integration, to enhance the understanding of the molecular pathology of EBV-associated lymphomas and optimize personalized treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。
